AperçuGraphiqueActualitésTraderScreen

JP Morgan Put 1025 REGN 15.11.202.../  DE000JT161Z6  /

EUWAX
31/10/2024  08:33:56 Chg.- Bid22:00:33 Demandez à22:00:33 Sous-jacent Prix d'exercice Date d'expiration Type d'option
0.990EUR - -
Bid taille: -		 -
Ask la taille: -		 Regeneron Pharmaceut... 1,025.00 - 15/11/2024 Put
GlobeNewswire 26/08 Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Fol...
GlobeNewswire 26/08 Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadersh...
GlobeNewswire 21/08 Regeneron Provides Update on Biologics License Application for Linvoseltamab
GlobeNewswire 07/08 Regeneron Announces Investor Conference Presentations and Oncology Investor Webcast
GlobeNewswire 01/08 Regeneron Reports Second Quarter 2024 Financial and Operating Results
GlobeNewswire 31/07 Regeneron Announces the 2024 Winners of the Regeneron Prize for Creative Innovation
GlobeNewswire 03/07 Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients...
GlobeNewswire 28/06 Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphom...
GlobeNewswire 27/06 Regeneron to Report Second Quarter 2024 Financial and Operating Results and Host Conference Call and...
GlobeNewswire 26/06 Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esoph...
GlobeNewswire 16/06 Updated Linvoseltamab Data Showcase Continued Deepening of Responses in Patients with Heavily Pre-Tr...
GlobeNewswire 11/06 Kevzara® (sarilumab) Approved by FDA for the Treatment of Active Polyarticular Juvenile Idiopathic A...
GlobeNewswire 31/05 Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPD
GlobeNewswire 31/05 Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type ...
GlobeNewswire 23/05 Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Com...
GlobeNewswire 20/05 Dupixent® (dupilumab) Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS...
GlobeNewswire 17/05 More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International ...
GlobeNewswire 13/05 Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chroni...
GlobeNewswire 08/05 Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound G...
GlobeNewswire 06/05 Regeneron Announces Investor Conference Presentations
GlobeNewswire 02/05 Regeneron Reports First Quarter 2024 Financial and Operating Results
GlobeNewswire 29/04 EYLEA® HD (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Sustained and Clinically Mean...
GlobeNewswire 25/04 Regeneron and Mammoth Biosciences Collaborate to Pursue Next-Generation CRISPR-Based Gene Editing fo...
GlobeNewswire 24/04 Regeneron to Showcase Progress in Advancing Novel Investigational Treatment Approaches for a Broad R...
GlobeNewswire 22/04 Regeneron to Highlight Advances in Genetic Medicine Research at American Society of Gene and Cell Th...